Total Payments
$1.7M
2024 Payments
$144,187
Companies
55
Transactions
899
Medicare Patients
12,137
Medicare Billing
$3.2M
Payment Breakdown by Category
Other$1.1M (64.2%)
Consulting$487,599 (29.2%)
Travel$80,941 (4.8%)
Food & Beverage$28,750 (1.7%)
Education$230.53 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 164 | 63.0% |
| Consulting Fee | $487,599 | 44 | 29.2% |
| Travel and Lodging | $80,941 | 234 | 4.8% |
| Food and Beverage | $28,750 | 429 | 1.7% |
| Honoraria | $20,255 | 19 | 1.2% |
| Education | $230.53 | 9 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Seagen Inc. | $1.0M | 159 | $0 (2023) |
| GlaxoSmithKline, LLC. | $191,243 | 132 | $0 (2024) |
| BeiGene USA, Inc. | $171,503 | 114 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $56,554 | 70 | $0 (2024) |
| Seattle Genetics, Inc. | $50,639 | 43 | $0 (2019) |
| PFIZER INC. | $30,145 | 34 | $0 (2024) |
| SOBI, INC | $18,465 | 21 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $18,205 | 28 | $0 (2021) |
| Epizyme, Inc., | $16,155 | 15 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $13,662 | 20 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $144,187 | 126 | BeiGene USA, Inc. ($81,946) |
| 2023 | $241,350 | 216 | Seagen Inc. ($107,744) |
| 2022 | $507,633 | 168 | Seagen Inc. ($395,672) |
| 2021 | $583,067 | 125 | Seagen Inc. ($517,189) |
| 2020 | $63,074 | 65 | Seagen Inc. ($20,379) |
| 2019 | $70,770 | 103 | JAZZ PHARMACEUTICALS INC. ($31,870) |
| 2018 | $55,733 | 66 | Seattle Genetics, Inc. ($25,430) |
| 2017 | $4,161 | 30 | Otsuka Pharmaceutical Co., Ltd. ($1,855) |
All Payment Transactions
899 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $85.64 | General |
| Category: Oncology | ||||||
| 12/07/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $78.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| 12/05/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.86 | General |
| Category: Hematology/Oncology | ||||||
| 10/24/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | In-kind items and services | $1,052.69 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | In-kind items and services | $272.57 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,850.00 | General |
| Category: Oncology | ||||||
| 10/17/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $993.67 | General |
| Category: Oncology | ||||||
| 10/17/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $357.96 | General |
| Category: Oncology | ||||||
| 10/17/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $306.66 | General |
| Category: Oncology | ||||||
| 10/01/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,200.00 | General |
| Category: Oncology | ||||||
| 10/01/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $726.59 | General |
| Category: Oncology | ||||||
| 10/01/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $359.96 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: Oncology | ||||||
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,670.00 | General |
| Category: Oncology | ||||||
| 09/18/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Consulting Fee | Cash or cash equivalent | $815.00 | General |
| Category: Oncology | ||||||
| 09/17/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $148.45 | General |
| Category: Oncology | ||||||
| 09/17/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 08/20/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 08/15/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: Oncology | ||||||
| 08/15/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $116.91 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 56 | 2,732 | 53,269 | $2.9M | $684,247 |
| 2022 | 62 | 3,079 | 55,863 | $3.6M | $802,731 |
| 2021 | 67 | 3,576 | 70,634 | $4.4M | $936,536 |
| 2020 | 57 | 2,750 | 41,788 | $3.1M | $799,836 |
Total Patients
12,137
Total Services
221,554
Medicare Billing
$3.2M
Procedure Codes
242
All Medicare Procedures & Services
242 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 36 | 9,400 | $1.3M | $406,440 | 31.5% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 14 | 4,360 | $331,940 | $102,892 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 222 | 698 | $256,864 | $64,263 | 25.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 169 | 218 | $154,126 | $22,553 | 14.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 224 | 787 | $15,740 | $6,602 | 41.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 112 | 276 | $43,332 | $6,366 | 14.7% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 31 | 31 | $33,077 | $5,677 | 17.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 227 | 726 | $26,136 | $5,493 | 21.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 33 | 70 | $17,290 | $4,358 | 25.2% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 45 | 246 | $14,760 | $4,133 | 28.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 144 | 396 | $25,344 | $4,090 | 16.1% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 36 | 115 | $16,445 | $3,966 | 24.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $15,598 | $3,751 | 24.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 43 | 57 | $14,250 | $3,499 | 24.6% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 13 | 10,710 | $53,550 | $3,414 | 6.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 49 | 66 | $22,704 | $3,402 | 15.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 119 | 254 | $15,240 | $3,325 | 21.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 22 | $10,912 | $3,030 | 27.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 37 | 48 | $15,024 | $2,287 | 15.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 109 | 183 | $19,764 | $2,260 | 11.4% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 12 | 14 | $7,000 | $1,891 | 27.0% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 33 | 34 | $27,914 | $1,809 | 6.5% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 15 | 19 | $12,483 | $1,722 | 13.8% |
| 77075 | Complete x-ray of body bones | Office | 2023 | 26 | 31 | $6,417 | $1,704 | 26.5% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 11 | 12 | $6,276 | $1,586 | 25.3% |
About Andrew Whiteley
Andrew Whiteley is a Internal Medicine healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2011. The National Provider Identifier (NPI) number assigned to this provider is 1225328743.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Andrew Whiteley has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $144,187 received in 2024. These payments were reported across 899 transactions from 55 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
As a Medicare-enrolled provider, Whiteley has provided services to 12,137 Medicare beneficiaries, totaling 221,554 services with total Medicare billing of $3.2M. Data is available for 4 years (2020–2023), covering 242 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Student in an Organized Health Care Education/Training Program, Medical Oncology
- Location Dallas, TX
- Active Since 04/18/2011
- Last Updated 04/19/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1225328743
Products in Payments
- ADCETRIS (Biological) $1.1M
- BRUKINSA (Drug) $171,503
- BLENREP (Biological) $140,035
- VYXEOS (Drug) $51,883
- OJJAARA (Drug) $48,644
- TIBSOVO (Drug) $22,980
- TAZVERIK (Drug) $16,155
- Doptelet (Drug) $15,584
- IMBRUVICA (Drug) $10,819
- JAKAFI (Drug) $7,188
- Vonjo (Drug) $5,128
- ELIQUIS (Drug) $5,092
- SARCLISA (Biological) $4,773
- DOPTELET (Drug) $4,405
- VENCLEXTA (Drug) $4,218
- RYDAPT (Drug) $3,287
- CALQUENCE (Drug) $3,262
- DARZALEX (Biological) $3,204
- clonoSEQ (Device) $2,026
- ONUREG (Drug) $1,842
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Dallas
Biff Palmer, Md, MD
Internal Medicine — Payments: $980,569
Internal Medicine $980,569
Dr. Robert Gottlieb, M.d. Ph.d, M.D. PH.D
Internal Medicine — Payments: $832,284
Internal Medicine $832,284
Dr. Ronan Kelly, Md, MD
Internal Medicine — Payments: $813,092
Internal Medicine $813,092
Dr. Gates Colbert, M.d, M.D
Internal Medicine — Payments: $801,349
Internal Medicine $801,349
Dr. Zoran Kurepa, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $743,379
Internal Medicine $743,379
Dr. Edward Pearson, Md, MD
Internal Medicine — Payments: $728,183
Internal Medicine $728,183